BRKRNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31Also trades as BRKRP
BRUKER CORP
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$55.37+0.57 (+1.04%)
Close on Oct 19, 2026
- Market cap
- $8.43B
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Gross margin
45.9%−1.4 pts over 5 years
Operating margin
2.0%−10.5 pts over 5 years
Net margin
-0.3%−8.2 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +2.1% | +10.7% | +11.6% | +7.8% | |
| Gross profit | -4.4% | +6.5% | +10.9% | +8.3% | |
| Operating income | -73.1% | -46.0% | -22.8% | -7.3% | |
| Free cash flow | -68.2% | -33.2% | -28.7% | -14.0% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | 21.7% | 16.9% | -0.4% | |
| Return on assets | 8.7% | 5.4% | -0.1% | |
| Current ratio | 2.43 | 2.43 | 1.73 | |
| Debt to equity | 0.60 | 0.88 | 0.76 | |
| Net debt to EBITDA | 0.28× | 0.48× | 5.44× | |
| Interest coverage | 13.8× | 17.2× | 1.1× | |
| Inventory turnover | 2.0× | 1.7× | 1.7× | |
| Capex to revenue | 2.3% | 4.9% | 2.6% | |
| Diluted shares | 162M | 0M | 152M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Bruker generated $1.29B from operations and spent $1.25B on capital expenditure, dividends and share buybacks. 43% of that went back into the business.
Generated
$1.29B
Used
$1.25B
Capital expenditure$534.20M43%Dividends$136.40M11%Share buybacks$578.70M46%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-0.3%
×Asset turnover0.57×
×Equity multiplier2.84×
=Return on equity, FY2025-0.4%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -0.3% | 0.57× | 2.84× | -0.4% |
| FY2024 | 3.4% | 0.67× | 3.18× | 7.2% |
| FY2023 | 14.4% | 0.75× | 3.16× | 34.3% |
| FY2022 | 11.7% | 0.70× | 3.32× | 27.2% |
| FY2021 | 11.5% | 0.72× | 3.30× | 27.3% |
| FY2020 | 7.9% | 0.68× | 3.12× | 16.9% |
| FY2019 | 9.5% | 0.85× | 2.72× | 21.9% |
| FY2018 | 9.5% | 0.93× | 2.51× | 22.2% |
| FY2017 | 4.5% | 0.94× | 2.66× | 11.1% |
| FY2016 | 9.5% | 0.91× | 2.51× | 21.7% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 9 tests passed in fiscal 2025. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$8.60M
- Cash generatingOperating cash flow above zero$134.10M
- Return on assets improvedROA up on the prior year2.7% → -0.1%
- Earnings backed by cashOperating cash flow above net income$134.10M vs -$8.60M
- Less leverageLong-term debt to assets fell35.5% → 29.7%
- Better liquidityCurrent ratio rose1.60 → 1.73
- No dilutionShare count did not rise150M → 152M
- Gross margin improvedGross margin up on the prior year49.00% → 45.91%
- More efficientAsset turnover rose0.79 → 0.59